The stock of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is a huge mover today! The stock decreased 1.81% or $0.06 on October 5, hitting $3.26. About 341,180 shares traded hands. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has declined 44.94% since March 2, 2016 and is downtrending. It has underperformed by 53.20% the S&P500.
The move comes after 6 months negative chart setup for the $67.48M company. It was reported on Oct, 5 by Barchart.com. We have $2.90 PT which if reached, will make NASDAQ:ADMP worth $7.42M less.
Analysts await Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to report earnings on November, 14.
According to Zacks Investment Research, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California.”
More news for Adamis Pharmaceuticals Corp (NASDAQ:ADMP) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on April 25, 2011. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on May 16, 2012 is yet another important article.
ADMP Company Profile
Adamis Pharmaceuticals Corporation, incorporated on April 22, 2004, is a pharmaceutical company. The Firm is engaged in the development of its specialty pharmaceutical products. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.